As your business grows, Fidelity is there to help with equity management solutions to meet your needs, from startup to IPO and beyond.
Put our experience to work.
One analyst speculated that, going forward, Prasad may be less “heavy-handed” in reviewing rare disease therapies given the public backlash to the agency’s confrontation with Sarepta.
The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a multibillion-dollar deal that hadn’t yet paid dividends.
Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as “additional breathing room” ahead of a debt maturity in 2027.
GSK transformed drug development by investing in claims data early and revealing critical treatment dynamics. Learn their approach to securing budget, maximizing ROI and de-risking programs in this webinar.
